GSK has patented a method using RNA in liposomes to elicit an antibody response against various immunogens like respiratory syncytial virus and influenza virus A. Administered intramuscularly, the composition includes specific lipids and is effective for immunization in humans and cows. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Liposomal rna immunization for eliciting antibody response
A recently granted patent (Publication Number: US11883534B2) discloses a method for eliciting an antibody response against an immunogen in a subject by administering a pharmaceutical composition intramuscularly. The composition includes ribonucleic acid (RNA) molecules encoding the immunogen, such as various virus immunogens, and lipid particles with specific components. The lipid particles encapsulate the RNA molecules and have a defined size range. The method involves contacting the pharmaceutical composition with skeletal muscle in human or cow subjects to trigger the desired antibody response.
Furthermore, the patent claims detail additional features of the method, such as the specific structure of the RNA molecules, including a cap structure and modified nucleotides. The lipid particles contain a cationic lipid with a specific pKa range and a PEG-conjugated lipid. The method also aims to elicit a cell-mediated immune response against the immunogen and involves administering multiple unit doses of the pharmaceutical composition sequentially. The patent provides a detailed procedure for determining the pKa of the cationic lipid used in the lipid particles. Overall, the method described in the patent aims to effectively stimulate an immune response against various immunogens through the intramuscular administration of a specific pharmaceutical composition containing RNA molecules and lipid particles with defined characteristics.
To know more about GlobalData’s detailed insights on GSK, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
